2017 ASCO Meeting Highlights in Pancreatic Cancer

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: June 30, 2017
Expiration Date: June 30, 2018

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

This activity will describe eight clinically meaningful studies in pancreatic cancer that were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Participants will have the opportunity to review summaries of the clinical data, including commentary from investigators, regarding the significance of the data and its impact on practice. The presentations will provide an overview of investigational agents as well as combination therapies, in both the first-line and second- line, in the advanced/metastatic setting.

Target Audience

This activity is designed for multidisciplinary health care providers in the community setting, including oncologists, pharmacists, and associated multidisciplinary clinicians who may provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with pancreatic cancer
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in pancreatic cancer
  • Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in pancreatic cancer

Agenda

Highlights of:

  • CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC)
  • A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPAC) patients (pts)

Presenter: Tanios Bekaii-Saab, MD

Highlight of:

  • Results of the phase III ESPAC-4 study

Presenter: Alok A. Khorana, MD

Highlights of:

  • Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma (Abstract 4007)
  • Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513
  • Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

Presenter: Philip A. Philip, MD

Highlights of:

  • Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. (Abstract e15779)
  • Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (abstract 4109)

Presenter: Ramesh Ramanathan, MD

Highlight of:

  • Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

Presenter: Andrea Wang-Gillam, MD 

Instructions for Participation and Credit

This activity is eligible for credit through June 30, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Tanios Bekaii-Saab, MD, FACP
Professor
Mayo Clinic College of Medicine and Science
Co-Leader, Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Division of Hematology and Oncology
Mayo Clinic
Phoenix, Arizona

Dr. Tanios Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon, followed by a residency in internal medicine at Indiana University Medical Center in Indianapolis. He completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center, Boston. Dr. Bekaii-Saab joined the faculty at the Mayo Clinic in May 2016 as Co-Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, and Professor at the Mayo Clinic College of Medicine and Science. He is also a Senior Associate Consultant, Division of Hematology and Oncology. He was previously at Ohio State University - Arthur G. James Cancer Hospital and Solove Research Institute as a tenured Professor of Medicine and Pharmacy, and Section Chief for the Gastrointestinal Cancer Program.

Dr. Bekaii-Saab is actively involved in the American Society of Clinical Oncology, American Association for Cancer Research, and the American Society for Clinical Pharmacology and Therapeutics. Additionally, he is the co-leader for the hepato-biliary cancer committee for the Alliance cooperative group, and is the Alliance representative for the National Cancer Institute (NCI) hepato-biliary national cancer task force. He is also the SWOG representative for the NCI pancreatic cancer task force. In addition, Dr. Bekaii-Saab is the senior executive leader for solid tumor research and GI cancer committee co-leader for the Mayo Clinic sponsored ACCRU network which includes more than 110 institutions and practices from all over the US, Canada, and Singapore. Dr. Bekaii-Saab has served as a reviewer for more than 50 of the most prestigious journals and has authored more than 350 peer-reviewed publications, abstracts, and book chapters in journals such as Journal of Clinical Oncology, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

Dr. Bekaii-Saab’s research interests include experimental therapeutics/translational research focused on hepatobiliary and pancreatic malignancies, molecular targeted and immune therapies. He is the principal investigator on numerous clinical trials supported through research grants from the NCI and the NCCN. He is also the recipient of numerous research grants from various industry partners. Dr. Bekaii-Saab is also the recipient of the prestigious NCI clinical investigator team leadership award and the ASCO leadership program development award. Additionally, he has been listed in U.S. News and World Report’s Top Doctors and is one of the Best Doctors in America.

Alok A. Khorana, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Dr. Alok Khorana received his medical degree from Maharaja Sayajirao University’s Medical College in Baroda (Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology/oncology at the University of Rochester, New York. He is a Fellow of the American College of Physicians. Dr. Khorana is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services and Strategy of the Taussig Cancer Institute, and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio.

Dr. Khorana is chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGC) Pancreas Cancer Working Group and co-chair of the ASCO Guidelines Panel on Resectable Pancreas Cancer. He also serves on the ASCO Scientific Program Committee and multiple ASCO guideline panels. He is past chair of the ASCO CPGC, and the International Society on Thrombosis and Haemostasis Scientific Subcommittee on Hemostasis and Malignancy. In addition, he has previously served as a member of the US Pharmacopoeia Oncology Expert Committee. Dr. Khorana has been published in a variety of journals including New England Journal of Medicine, Journal of American Medical Association (JAMA), Journal of Clinical Oncology, Blood, Journal of the National Cancer Institute, Clinical Cancer Research, PLoS One, and JAMA Internal Medicine. He has co-authored chapters in multiple textbooks including Cecil Essentials of Medicine and DeVita’s Cancer: Principles and Practice of Oncology and is co-editor of the book Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention and Treatment.

Dr. Khorana’s clinical and translational research programs focus on predictive factors and drug development in gastrointestinal cancers and cancer-associated thrombosis and has been funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Porter Family Fund, the Scott Hamilton CARES Initiative, and the V Foundation.

Philip A. Philip, MD, PhD, FRCP, FABC
Professor of Oncology, Pharmacology and Medicine
Kathryn Cramer Endowed Chair in Cancer Research
Vice President of Medical Affairs
Department of Oncology
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

Dr. Philip received his medical degree from the University of Baghdad, College of Medicine in Iraq, and his PhD in clinical pharmacology and pharmacogenetics at the University of London Guy’s Hospital Medical School in the UK. He completed a residency at the University of Baghdad, and a fellowship in medical oncology at the University of Oxford and the MD Anderson Cancer Center in Houston, Texas. Dr. Philip is Professor of Oncology, Pharmacology and Medicine, the Endowed Dr. Kathryn Cramer Professor of Cancer Research, as well as Vice President of Medical Affairs at the Karmanos Cancer Institute at Wayne State University School of Medicine in Detroit

Dr. Philip is USA board-certified in medical oncology and is a fellow of the Royal College of Physicians in the UK. He is leader of hepatopancreatic biliary track, a member of planning committee of ASCO GI 2017, and chairs the pancreatic cancer committee at the Southwest Oncology Group (SWOG). In addition, he holds membership in the International Liver Cancer Association, American Pancreatic Association, American Society of Clinical Oncology, American Association for Cancer Research, and the Pharmacology and Molecular Mechanisms Group (PAMM) of the EORTC, among others.

A frequent national and international lecturer, Dr. Philip authored over 200 manuscripts, review articles, editorials, and co-edited a book on pancreatic cancer. His major research interests are in the development of new therapies for gastrointestinal and neuroendocrine cancers with a special focus on pancreatic cancer. He has been the principal investigator on numerous local and national clinical trials in GI cancers.

Ramesh K. Ramanathan, MD
Director, GI Medical Oncology
Vice Chair of Research
Division of Hematology/Oncology
Mayo Clinic
Phoenix, Arizona

Dr. Ramesh Ramanathan is a medical oncologist and Director of the GI Medical Oncology program and Vice Chair of Research for the Division of Hematology/Oncology at Mayo Clinic, Phoenix, Arizona. He is also the Associate Director of the Early Therapeutics Program for the Mayo Clinic Cancer Center. Dr. Ramanathan holds appointments as a Professor of Medicine at the Mayo Medical School with a joint appointment at the Translational Genomics Research Institute (TGEN). Prior to joining Mayo Clinic, he served as the medical director of the Virginia G. Piper Cancer Center - Clinical Trials Program, in Scottsdale, Arizona from 2007-2014.

Dr. Ramanathan specializes in the treatment of GI cancers with a focus on pancreatic and colon cancers. His research interests are in new drug development. In the last 20 years, Dr. Ramanathan has been involved in the development of a number of new drugs and treatments such as oxaliplatin and nab-paclitaxel for GI cancers. He has published over 160 papers in peer-reviewed journals. He is an executive committee member and the former chair for the pancreatic cancer research group (PCRT) and is a GI committee member for SWOG. Dr. Ramanathan is an editorial board member for Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, and Gastrointestinal Cancer Research, and is an ad hoc reviewer for a number of other journals.

Andrea Wang-Gillam, MD, PhD
Associate Professor
Clinical Director
GI Oncology Program
Washington University
St. Louis, Missouri

Dr. Andrea Wang-Gillam received her medical degree and PhD from the University of Arkansas College of Medicine. She completed her internship in internal medicine at the Cleveland Clinic Foundation, and her residency in internal medicine and fellowship in hematology/oncology from the University of Arkansas for Medical Sciences. She is an Associate Professor and the Clinical Director for the GI Oncology Program in the Division of Oncology at Washington University in St. Louis, Missouri.

Board certified in internal medicine and medical oncology, Dr. Wang-Gillam holds memberships in the American Society of Clinical Oncology, the American Pancreatic Cancer Association, and the American Association for Cancer Research. Her research focuses on novel therapy developments in pancreatic cancer, and she has developed several investigator-initiated studies in pancreatic cancer. She also has served as a principal investigator for multiple pancreatic cancer studies.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-17-155-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 17-155-056

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Tanios Bekaii-Saab has received honoraria as a consultant from Celgene Corporation, Ipsen, and Merrimack Pharmaceuticals, Inc.

Dr. Alok Khorana has received honoraria as a consultant from Bayer AG, Janssen Pharmaceuticals, Inc., LEO Pharma Inc., Pfizer Inc., and Sanofi. He has received grant support related to research activities from Amgen Inc., Janssen, and LEO.

Dr. Philip has received honoraria as a consultant from Celgene Corporation, Cornerstone Therapeutics Inc., Eli Lilly and Company, Halozyme, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., and Merrimack Pharmaceuticals, Inc., as well as speakers’ bureau activities from Amgen Inc., Celgene, and Eli Lilly. He has received grant support related to research activities from Bayer AG, Celgene, Eli Lilly, Halozyme, Merck, and Novartis.

Dr. Ramesh Ramanathan has received honoraria related to formal advisory activities from Novocure and Pharmacyclics, Inc. He has received grant support related to research activities from AbbVie Inc., Celgene Corporation, Merrimack Pharmaceuticals, Inc., and Superlabs.

Dr. Andrea Wang-Gillam has received honoraria related to formal advisory activities from Merrimack Pharmaceuticals, Inc., NewLink Genetics Corporation, and Pfizer Inc.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved